Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | MC4R | P32245 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1548187 | 0.85 | LMNA (0.52) | SPHK2MEN1KMT2ALMNAHTT | |
| SCHEMBL4995901 | 0.85 | SPHK2 (0.46) | SPHK2MEN1KMT2ALMNAHTT | |
| SCHEMBL2734576 | 0.80 | ESR1 (0.48) | SPHK2MEN1KMT2ALMNAHTT | |
| SCHEMBL1549039 | 0.74 | LMNA (0.49) | SPHK2MEN1KMT2ALMNAHTT | |
| SCHEMBL1548196 | 0.73 | LMNA (0.48) | SPHK2MEN1KMT2ALMNAHTT | |
| SCHEMBL1548830 | 0.73 | SPHK2 (0.69) | SPHK2MEN1KMT2ALMNAHTT | |
| SCHEMBL1548627 | 0.72 | LMNA (0.47) | SPHK2MEN1KMT2ALMNAHTT | |
| SCHEMBL4761609 | 0.71 | LMNA (0.50) | SPHK2MEN1KMT2ALMNAHTT | |
| SCHEMBL4717890 | 0.69 | MEN1 (0.50) | SPHK2MEN1KMT2ALMNAHTT | |
| SCHEMBL1548319 | 0.69 | SPHK2 (0.77) | SPHK2MEN1KMT2ALMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080167352-A1 | Sphingosine Kinase Inhibitors | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2008-07-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167352-A1 | Sphingosine Kinase Inhibitors | SPHK1, SPHK2, S1PR1 | SPHK2 2/4885MEN1 2111/4885KMT2A 3321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.